INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for March 4, 2021 at 4:30 PM ET to discuss its fourth quarter and full year 2020 results. The company is focused on harnessing the innate immune system to develop treatments for various diseases, including COVID-19, cancer, Alzheimer's, and NASH. The call can be accessed via dial-in or a live webcast, with a replay available until March 11, 2021.
For more information about INmune Bio, visit www.inmunebio.com.
INmune Bio (NASDAQ: INMB) has released interim data from its Phase 1b trial showing that XPro1595 significantly reduces neuroinflammation and improves biomarkers in Alzheimer’s disease patients after three months of therapy. Key results indicate decreased CSF levels of neuroinflammatory markers with p-values less than 0.0001, while MRI findings suggest notable neuroimaging improvements. The company plans to initiate a blinded randomized Phase 2 study before the end of the year. A Key Opinion Leader webinar is scheduled for January 21, 2021, to discuss these findings in detail.
INmune Bio, Inc. (NASDAQ: INMB) announces a Key Opinion Leader (KOL) webinar on January 21, from 8:00 AM – 9:00 AM ET, to showcase expanded biomarker results from its Phase 1b clinical trial of XPro1595, targeting neuroinflammation in Alzheimer's patients. The trial aims to demonstrate a reduction in neuroinflammation through XPro1595, with updates presented by key experts including RJ Tesi, M.D., and Dr. CJ Barnum. The company previously noted a decrease in neuroinflammation as measured by the novel biomarker white matter free water (WMFW).
Bexion Pharmaceuticals has announced the appointment of Dr. RJ. Tesi to its Board of Directors. Dr. Tesi, currently the President and CEO of INmune Bio (NASDAQ: INMB), brings extensive experience in biotech entrepreneurship and clinical drug development. His leadership roles in various biotech firms and as a surgeon since 1982 position him to significantly influence Bexion's ongoing programs. Dr. Tesi expressed enthusiasm about joining a company with promising technology across therapeutic areas, forecasting potential success in the competitive biotech landscape.
INmune Bio (NASDAQ: INMB) announced the dosing of its first patient in a Phase 2 clinical trial for Quellor™, aimed at treating pulmonary complications from COVID-19. Quellor™ is a selective sTNF inhibitor designed to mitigate the immune response associated with COVID-19 infections. The trial will involve 366 high-risk patients, comparing standard care with Quellor™ administration. Key endpoints include the need for mechanical ventilation and other severe complications. The trial's outcomes could inform further development of Quellor™ and its potential market impact.
INmune Bio (NASDAQ: INMB) reported its Q3 2020 financial results, showing a net loss of approximately $4.7 million, up from $3.1 million in Q3 2019. R&D expenses rose to $2.4 million from $1.2 million, while G&A expenses increased to $2.5 million from $1.9 million. The company received a $2.9 million NIH grant for a Phase 2 study of XPro1595 in treatment-resistant depression and reported a 40.6% decrease in neuroinflammation in Alzheimer’s patients from Phase 1b trials. INMB completed a $25 million stock offering, raising net proceeds of $23.1 million.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call on November 5, 2020, at 4:30 PM ET to discuss third quarter results for the period ending September 30, 2020, and provide a corporate update. The call will allow stakeholders to gain insights regarding the company’s performance and future outlook. INmune Bio focuses on developing treatments that harness the innate immune system, with clinical trials for products targeting conditions like COVID-19, cancer, Alzheimer's, and depression.
INmune Bio (NASDAQ: INMB) announced new findings from its Phase Ib study targeting neuroinflammation in Alzheimer's patients, presented by CJ Barnum PhD at the International Conference on Alzheimer’s Drug Discovery. Preliminary results indicate that the treatment XPro1595 reduced White Matter Free Water (WMFW) by 40% on average in the arcuate fasciculus, a key brain area for language. The trial is ongoing, focusing on various biomarkers of neuroinflammation. XPro1595 aims to selectively inhibit soluble TNF, which is crucial in neurodegenative diseases.
INmune Bio, a clinical-stage immunology company, announced a Key Opinion Leader (KOL) webinar on treatment resistant depression (TRD) scheduled for September 29, 2020, at 1:00 PM ET. The webinar will cover neuroinflammation's role in TRD, featuring experts Dr. Charles Raison and Dr. John Schneider. Additionally, the company received a $2.9 million SBIR grant from the NIH for a Phase 2 study of its lead candidate, XPro1595, aimed at tackling TRD. Registration for the live webinar is available online.
INmune Bio has secured a $2.9 million Small Business Innovation Research (SBIR) grant from the NIH to support a Phase 2 study of XPro1595, a treatment for treatment-resistant depression (TRD). This randomized, blinded study will involve 100 patients and utilize neuroimaging to explore neuroinflammation's role in TRD. With the study's sites at Emory University and the University of Alabama, the funding will be distributed over the next three years. The findings could have significant implications for treating TRD and related neurodegenerative diseases.